生物传感器分析技术及其在阿尔茨海默病药物研发中的研究进展

Biosensor analysis technology and its research progress in drug development of Alzheimer's disease

生物传感器分析技术是一类可将生物反应转换为光电信号的高特异性技术,在阿尔茨海默病(Alzheimer's disease,AD)药物研发中,针对AD不同假说、不同靶点,该技术在确证靶标、筛选活性化合物方面发挥了重要作用。该文简述AD发病机制与治疗药物现况,重点介绍了AD药物研发中常用的表面等离子共振技术(surface plasmon resonance,SPR)、生物膜干涉技术(biolayer interferometry,BLI)与荧光分析技术这三类生物传感器分析技术,阐释其基本原理及其应用进展,并总结各自的优势与局限。

Biosensor analysis technology is a kind of technology with high specificity that can convert biological reactions into optical and electrical signals.In the development of drugs for Alzheimer's disease(AD),according to different disease hypotheses and targets,this technology plays an important role in confirming targets and screening active compounds.This paper briefly describes the pathogenesis of AD and the current situation of therapeutic drugs,introduces three biosensor analysis techniques commonly used in the discovery of AD drugs,such as surface plasmon resonance(SPR),biolayer interferometry(BLI)and fluorescence analysis technology,explains its basic principle and application progress,and summarizes their advantages and limitations respectively.